CHST11

CHST11 (C4ST-1) is a Golgi-resident chondroitin-4-O-sulfotransferase of the HNK1 sulfotransferase family that catalyzes 4-O-sulfation of GalNAc residues on chondroitin chains, thereby setting the sulfation pattern of chondroitin sulfate proteoglycans across skeletal, vascular, adipose, neural, and tumor tissues (PMID:15273723, PMID:21284936). Its transcription is a convergence point for developmental signaling: BMP2/BMP4 induce CHST11 through a phospho-Smad3 promoter element, and ARSB-controlled C4S sulfation feeds back on BMP4 availability to govern this loop, while Wnt9A opposes induction (PMID:12351172, PMID:25511584); TGFβ likewise upregulates CHST11 through conserved cis-regulatory modules and, in vascular smooth muscle, via a Nox/ROS/MAPK/Smad2-linker phosphorylation cascade (PMID:19937589, PMID:30417274); PPARγ directly binds two intronic sites to drive CHST11 during adipogenesis (PMID:23696875); and oncogenic HRAS represses CHST11 and C4S, with re-expression rescuing the proliferation and elastogenesis defects of Costello syndrome fibroblasts (PMID:22317973). Through its C4S product CHST11 acts on diverse downstream effectors: it is required for lipoprotein-lipase binding and lipid accumulation in adipocytes (PMID:23696875), for CSPG4-dependent glioblastoma invasion (blockable by a C4S-binding peptide) (PMID:37559985), and for suppression of osteoblast differentiation via a Wnt3a/β-catenin/p53 axis (PMID:41656089). CHST11 expression is post-transcriptionally restrained by KIAA1429/VIRMA-mediated m6A methylation that recruits YTHDF2 to destabilize its mRNA, and in DLBCL this loss couples to reduced MOB1B and inactivation of Hippo-YAP signaling (PMID:37076815). Loss-of-function in humans—through homozygous deletion or an in-frame deletion of five conserved residues—causes severe skeletal malformation syndromes, establishing CHST11 as essential for skeletal morphogenesis (PMID:26436107, PMID:29514872).

1. 2002 Medium

   Established CHST11 as a developmentally regulated effector by showing it is induced downstream of BMP2 in a differentiation-dependent manner, placing a sulfotransferase within morphogen signaling.

   Evidence Gene trap screen in mouse ES cells with BMP2/activin/nodal treatment across differentiation states

   PMID:12351172

   Open questions at the time

   • Did not define the promoter elements mediating BMP2 induction
   • No enzymatic or sulfation-pattern readout linked to the induction
2. 2004 Medium

   Identified CHST11 as a Golgi HNK1-family sulfotransferase and implicated it in hematopoietic malignancy via a translocation disrupting intron 2 and producing truncated IGH/CHST11 fusion transcripts.

   Evidence FISH, Southern/Northern blot, and 5'/3'-RACE on B-CLL tumor RNA

   PMID:15273723

   Open questions at the time

   • Functional consequence of the truncated protein not tested enzymatically
   • Causality between fusion and transformation not established
3. 2009 Medium

   Mapped functional cis-regulatory modules and showed TGFβ positively regulates CHST11 transcription, defining a second morphogen input to the locus.

   Evidence Conservation analysis and luciferase reporter assays in HEK293T and NmuMG cells with TGFβ

   PMID:19937589

   Open questions at the time

   • Transcription factors binding the modules not identified here
   • Endogenous-locus relevance beyond reporters not shown
4. 2011 Medium

   Distinguished CHST11's biological role from the related dermatan enzyme CHST14 by showing CHST11 loss does not impair neural stem cell behavior, indicating tissue-specific dispensability.

   Evidence Chst11- vs Chst14-deficient mouse NSC proliferation, migration, and neurogenesis assays

   PMID:22159417

   Open questions at the time

   • Negative result does not exclude roles in other neural contexts
   • No measurement of residual CS sulfation in KO NSCs
5. 2011 Medium

   Linked CHST11 expression to chondroitin sulfate chain elongation in disease by correlating its upregulation with progressive atherosclerotic remodeling.

   Evidence qRT-PCR and CS chain-length gel filtration plus IHC in LDLr KO mouse aortas over a western diet time course

   PMID:21284936

   Open questions at the time

   • Correlative; no causal CHST11 manipulation in lesions
   • Cell type driving the expression change not resolved
6. 2012 High

   Defined CHST11 as a target negatively regulated by oncogenic HRAS and demonstrated its functional importance by rescuing Costello syndrome fibroblast phenotypes.

   Evidence Reciprocal HRAS gain/loss, pharmacological HRAS inhibition, and C4ST-1 re-expression rescue in patient fibroblasts with proliferation/elastogenesis assays

   PMID:22317973

   Open questions at the time

   • Transcriptional mechanism of HRAS repression not pinpointed
   • Sulfation substrate mediating elastogenesis rescue not identified
7. 2013 Medium

   Established direct PPARγ transcriptional control of CHST11 and a downstream metabolic role in adipocyte lipid handling via LPL binding.

   Evidence PPARγ ChIP at intronic sites, Chst11 siRNA in 3T3-L1 adipocytes, LPL activity and lipid accumulation assays

   PMID:23696875

   Open questions at the time

   • Direct requirement of C4S sulfation for LPL binding inferred, not biochemically proven
   • In vivo adipose relevance not tested
8. 2014 High

   Resolved a feedback loop in which ARSB and BMP4 control CHST11 at the promoter through phospho-Smad3, with Wnt9A as an opposing input.

   Evidence ARSB siRNA, BMP4 neutralization/recombinant BMP4, pSmad3 ChIP at the CHST11 promoter, Wnt9A siRNA in colonic epithelium and ARSB-deficient mice

   PMID:25511584

   Open questions at the time

   • Mechanism of Wnt9A repression not defined
   • Generality of the ARSB-BMP4 loop outside colonic epithelium unknown
9. 2016 Medium

   Connected CHST11 intronic OA-risk variants to differential enhancer activity and allele-specific transcription factor binding.

   Evidence Luciferase reporters plus EMSA/supershift for SP1, SP3, YY1, SUB1 at risk alleles rs835487/rs835488

   PMID:27391021

   Open questions at the time

   • Effect on endogenous CHST11 levels in cartilage not measured
   • Link to osteoarthritis pathology not functionally demonstrated
10. 2016 Medium

    Positioned CHST11 as a suppressor of hepatocellular carcinoma invasion and drug resistance acting upstream of MAPK signaling.

    Evidence Reciprocal KD/OE in MHCC97L/H cells, invasion and drug-sensitivity assays, MAPK inhibitor epistasis, in vivo antitumor assay

    PMID:26993826

    Open questions at the time

    • CS substrate mediating MAPK modulation not identified
    • Direction of regulation differs from invasion-promoting role elsewhere
11. 2018 Medium

    Detailed the TGFβ1 signaling route to CHST11 in vascular smooth muscle through Nox/ROS, MAPK, and Smad2 linker phosphorylation.

    Evidence Nox inhibition (DPI, apocynin), Western blots for Smad2 linker/MAPK, ROS assay, and CHST11 qRT-PCR in VSMCs

    PMID:30417274

    Open questions at the time

    • Promoter elements receiving this signal not mapped
    • Downstream CS/vascular consequence not measured
12. 2018 Medium

    Confirmed CHST11's essential role in skeletal morphogenesis through an autosomal recessive in-frame deletion removing five conserved residues.

    Evidence Homozygosity mapping and exome sequencing in a consanguineous family with brachydactyly/syndactyly syndrome

    PMID:29514872

    Open questions at the time

    • Enzymatic effect of the deletion not biochemically assayed
    • Mechanistic link from sulfation loss to digit patterning not defined
13. 2023 High

    Established post-transcriptional control of CHST11 by m6A methylation and its coupling to oncogenic signaling in lymphoma.

    Evidence KIAA1429 CRISPR KO/dCas9 activation, MeRIP-seq, RIP, RNA-stability and Co-IP assays, and xenografts tracing KIAA1429→m6A-CHST11→YTHDF2→MOB1B→Hippo-YAP

    PMID:37076815

    Open questions at the time

    • How reduced CHST11 lowers MOB1B mechanistically not resolved
    • Whether the effect requires CHST11 enzymatic activity untested
14. 2023 Medium

    Demonstrated that CHST11-generated C4S on CSPG4 drives glioblastoma invasion and is therapeutically targetable.

    Evidence CHST11 KD/OE in GBM lines, invasion assays, C4S-binding peptide treatment in vitro and in orthotopic xenografts

    PMID:37559985

    Open questions at the time

    • Direct sulfation of CSPG4 by CHST11 inferred from correlation/function
    • Signaling pathway downstream of C4S-CSPG4 not delineated
15. 2025 Medium

    Identified CHST11 as a suppressor of osteoblast differentiation acting through altered 4S/6S ratio and a Wnt3a/β-catenin/p53 axis.

    Evidence C4ST-1 overexpression in osteoblasts with ALP/Akp2 readouts, chondroitinase ABC, and β-catenin/p53 pharmacological inhibition

    PMID:41656089

    Open questions at the time

    • How sulfation ratio activates Wnt3a not mechanistically defined
    • In vivo bone phenotype of overexpression not tested
16. 2025 Medium

    Extended CHST11's CS-sulfation role to brain function by linking hippocampal overexpression to impaired recognition memory rescuable by exercise.

    Evidence Viral hippocampal Chst11 overexpression, object recognition assay, exercise intervention, perineuronal net/aggrecan analysis (preprint)

    PMID:bio_10.1101_2025.11.14.688432

    Open questions at the time

    • Preprint, single lab, not peer-reviewed
    • Mechanism connecting CS sulfation to memory circuits not resolved

• It remains unresolved how CHST11's single enzymatic output—C4S sulfation—produces opposing context-dependent outcomes (tumor-suppressive in HCC, invasion-promoting in GBM; differentiation-suppressing in osteoblasts) and which substrate proteoglycans mediate each phenotype.
• No unified substrate-specificity map across tissues
• Enzymatic activity not directly tied to most disease phenotypes
• No structural model of the human enzyme in the corpus